STOCK TITAN

KKR to acquire Clinisupplies to accelerate growth and help build a leading international chronic care medical devices platform

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Rhea-AI Summary

KKR has announced its agreement to acquire Clinisupplies, a UK leader in continence care products, from Healthium. The transaction aims to bolster Clinisupplies' growth and expand its chronic care portfolio. Financial details remain undisclosed, but Clinisupplies will retain a minority stake. KKR plans to leverage its substantial resources, including the expertise of new board members like Claus Bjerre and Douglas Le Fort, to catalyze Clinisupplies' product and geographic expansion. This investment is part of KKR's $4 billion Health Care Strategic Growth Fund II.

Positive
  • KKR's acquisition is expected to enhance Clinisupplies' market position and innovation.
  • The addition of experienced board members will support strategic growth.
  • KKR's extensive global network can facilitate market expansion.
Negative
  • None.

KKR to support organic and inorganic growth to enhance Clinisupplies’ leadership position in collecting devices and expand its broader chronic care portfolio

Claus Bjerre, KKR Senior Advisor and former Chief Executive Officer of Atos Medical AB, to serve as Chairman of Clinisupplies’ Board of Directors

LONDON--(BUSINESS WIRE)-- KKR, a leading global investment firm, announced today that KKR has agreed to acquire Clinisupplies, a market leader in continence care products in the UK, from Healthium. Clinisupplies’ management team will continue to hold a minority position. Financial details of the transaction were not disclosed.

Clinisupplies is a UK-based manufacturer and distributor of continence care products, including urinary collecting devices and catheters. Clinisupplies’ products are supplied to hospitals and pharmacies, while also available for delivery to patients directly through its home delivery services – “Clinidirect.” Clinisupplies is headquartered in Watford, London, and employs over 400 employees.

Claus Bjerre, KKR Senior Advisor and former Chief Executive Officer of Atos Medical AB and former President, North America, of Coloplast, will serve as Chairman of Clinisupplies’ Board of Directors, where he will draw on his extensive sector experience and help guide the group on its future growth. In addition to leveraging KKR’s broader advisor and expert network, industry veteran Douglas Le Fort, who brings over 20 years of senior executive leadership experience, including as an Executive Committee Member at ConvaTec Group, will also join the Board of Directors.

Paul Cook, CEO of Clinisupplies, commented: “We are thrilled to form this strategic partnership with KKR, and to be welcoming Claus and Douglas to our Board. This transaction presents a pivotal growth opportunity for the business, and to be able to leverage their collective skills and expertise will be invaluable as we position the business for the future. With KKR’s global network and market knowledge, and with this strong suite of industry advisors, we will be able to expand into new products and geographies, helping to support more and more people and bringing us one step closer to our goal of becoming an international leader in the chronic care market.”

Claus Bjerre, KKR Senior Advisor, commented: “Clinisupplies has an industry leading track record as a fully integrated provider of continence care solutions to clinics and patients across the UK. Its business model covers the entire value chain, from R&D and manufacturing to direct-to-patient sales and distribution, allowing the group to continuously understand and address the evolving needs of patients, clinicians, and caregivers alike. I look forward to collaborating with Clinisupplies’ outstanding management team in pursuing its ambitious growth plans.”

Kugan Sathiyanandarajah, Managing Director and Head of Europe for KKR Health Care Strategic Growth, said: “Clinisupplies is a proven market leader in collecting devices in the UK with a differentiated business model. This investment is another example of our Health Care Strategic Growth platform strategy in collaboration with proven operators in a thematic area we have been following for some time. We are delighted to be bringing together an exceptional management team led by Paul with a highly experienced advisory suite led by Claus.”

KKR is investing in Clinisupplies through KKR Health Care Strategic Growth Fund II, a $4.0 billion fund focused on investing in high-growth health care companies. KKR has a long track record of supporting health care companies globally, having invested approximately $17 billion in the sector since 2004.

KKR was advised by Houlihan Lokey (financial advisor), Gibson, Dunn & Crutcher LLP (legal counsel), PWC (financial & tax) and BCG (commercial).

-- ends --

About KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com and on Twitter @KKR_Co.

About Clinisupplies

Clinisupplies is a leading UK-based manufacturer and supplier of medical appliances specialising in continence products for managing acute and chronic conditions. The company also offers a portfolio of bandages and garments for the treatment of wounds and chronic skin conditions. Employing over 400 people in the UK, China and India, Clinisupplies supplies its products to the NHS and delivers direct to patients’ homes through Clinidirect, its dispensing appliance contractor.

Clinisupplies is focused on developing products which are simple and discreet to use. Its product development team works with clinicians and patients to develop a strong product pipeline to be manufactured at its CE, ISO, US FDA approved facilities.

Please visit www.clinisupplies.co.uk for further information.

Media

FGS Global

Alastair Elwen / Sophia Johnston

Telephone: +44 20 7251 3801

Email: KKR-Lon@FGSGlobal.com

Source: KKR

FAQ

What is the significance of KKR acquiring Clinisupplies?

KKR's acquisition of Clinisupplies is poised to strengthen the company's leadership in the continence care market and expand its product offerings.

Who will lead Clinisupplies after the acquisition by KKR?

Claus Bjerre will serve as Chairman of Clinisupplies' Board of Directors following the acquisition.

What is the size of KKR's investment fund involved in this acquisition?

The acquisition is part of KKR's Health Care Strategic Growth Fund II, which is worth approximately $4 billion.

What is KKR's strategy concerning healthcare investments?

KKR focuses on high-growth healthcare companies, leveraging its management expertise and global network to foster growth.

KKR & Co. Inc.

NYSE:KKR

KKR Rankings

KKR Latest News

KKR Stock Data

142.12B
672.92M
24.01%
60.89%
1.29%
Asset Management
Investment Advice
Link
United States of America
NEW YORK